XML 85 R71.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
REVENUES:                
Total revenues $ 394,185     $ 378,143     $ 1,091,352 $ 1,127,646
EXPENSES:                
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) 51,591     63,099     150,248 183,215
Development programs:                
Alixorexton 25,812     11,873     67,461 34,918
LYBALVI 4,759     5,549     13,661 14,296
Other external R&D expenses 12,648     8,552     34,210 27,358
Total external R&D expenses 43,219     25,974     115,332 76,572
Internal R&D expenses:                
Employee-related 30,862     26,844     92,867 87,624
Occupancy 3,241     2,768     9,696 8,538
Depreciation 1,405     1,440     4,346 4,243
Other internal R&D expenses 3,012     2,866     8,685 10,175
Total internal R&D expenses 38,520     33,918     115,594 110,580
R&D expenses 81,739     59,892     230,926 187,152
Selling, general and administrative expenses:                
Selling and marketing expense 115,630     102,043     359,740 347,327
General and administrative expense 56,143     48,339     154,586 150,917
Total selling, general and administrative expense 171,773     150,382     514,326 498,244
Other segment income (expenses) [1] (6,321)     (11,975)     (3,529) (32,634)
NET INCOME FROM CONTINUING OPERATIONS 82,761     92,795     192,323 226,401
LOSS ON DISCONTINUED OPERATIONS, NET OF TAX 0     (414)     0 (5,834)
NET INCOME $ 82,761 $ 87,098 $ 22,464 $ 92,381 $ 91,358 $ 36,828 $ 192,323 $ 220,567
[1] “Other segment income (expenses)” during the three and nine months ended September 30, 2025 and 2024, includes “Amortization of acquired intangible assets”, “Other income, net” and “Income tax provision”.